<DOC>
	<DOCNO>NCT01211691</DOCNO>
	<brief_summary>This global , multicenter , open-label , repeat-dose , Phase 1/2 study consist Dose Escalation Phase ( Phase 1 ) Cohort Expansion Phase ( Phase 2 ) . In phase , KB004 administer IV infusion weekly part 21-day dosing cycle .</brief_summary>
	<brief_title>Study KB004 Subjects With Hematologic Malignancies ( Myelodysplastic Syndrome , MDS , Myelofibrosis , MF )</brief_title>
	<detailed_description>The purpose Phase 1 determine maximum tolerate dose ( MTD ) KB004 administer subject hematologic malignancy meet entry criterion . Phase 1 complete enrollment July 2014 , recommend Phase 2 dose 250 mg. AML 20 mg Cohort complete enrollment Dec 2014 . The purpose Phase 2 characterize preliminary clinical activity . The Phase 2 portion study consist two part : - Part A : Subjects AML MDS meet entry criterion - Part B : Subjects MF meet entry criterion</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Inclusion Criteria ( Phase 1 ) : Confirmed hematologic malignancy , include Acute Myeloid Leukemia ( AML ) , Chronic Lymphocytic Leukemia ( CLL ) , Chronic Myelogenous Leukemia ( CML ) , Acute Lymphocytic Leukemia ( ALL ) , Myelodysplastic Syndrome ( MDS ) , Multiple Myeloma ( MM ) , Myelofibrosis ( MF ) , Myeloproliferative Neoplasms ( MPN ) MDS/MPN overlap disease . ( Once Phase 2 start subject AML eligible inclusion Phase 1 portion study malignancy show cCbl mutation , trisomy 3 , trisomy 11 , inv ( 16 ) , elevate FLT3 . [ Other AML subject MDS longer eligible inclusion Phase 1 portion study ] ) . Key Inclusion Criteria ( Phase 2 ) : Part A : AML MDS patient acceptable level EphA3 expression Part B : MF patient acceptable level EphA3 expression Key Inclusion Criteria ( Both Phases ) : Confirmed hematologic malignancy refractory progress follow standard treatment , subject consider medically suitable receive standard care treatment refuse standard care treatment Acceptable level EphA3 expression Eastern Cooperative Oncology Group ( ECOG ) â‰¤1 Acceptable laboratory result Key Exclusion Criteria ( Both Phases ) : For subject AML , 2 prior therapy AML ( induction consolidation without hypomethylating agent give maintenance set consider 1 therapy ) History current central nervous system ( CNS ) involvement may increase risk bleed Recent major surgery Ongoing surgical wound heal complication Active clinically significant bleeding Uncontrolled hypertension Significant intercurrent illness Known history prolong bleed time platelet dysfunction Active infection require IV antibiotic , IV antifungal , IV antiviral within 2 week prior Cycle 1 , Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hematologic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Malignancies</keyword>
	<keyword>Myeloproliferative Neoplasms</keyword>
</DOC>